Nanomedicine Applications in Pediatric Cancer Therapy

Nanomedicine harnesses nanoscale carriers to improve the delivery, efficacy and safety of anticancer agents in children. Lipid-based, polymeric and inorganic nanoparticles are engineered to circulate stably, penetrate tumours and release therapeutic payloads in a controlled manner. By exploiting passive targeting through the enhanced permeability and retention effect and active targeting via surface ligands, these systems concentrate drugs at tumour sites while sparing healthy tissues. Such precision reduces systemic toxicity, mitigates long-term sequelae and enhances quality of life for paediatric patients. Applications span blood cancers, solid tumours and central nervous system malignancies, with ongoing efforts to overcome physiological barriers such as the blood–brain barrier. Preclinical models—from cell cultures to zebrafish and rodent assays—have demonstrated the potential of nanocarriers to improve pharmacokinetics, increase intracellular uptake and combine therapeutic modalities. Remaining challenges include scale-up manufacturing, regulatory harmonisation and rigorous evaluation of long-term safety. Continued interdisciplinary collaboration promises to translate these innovations into clinical practice, offering tailored, less toxic therapies for childhood cancers worldwide.

Research from Nature Portfolio

Researchers have developed lipid nanoemulsions incorporating an alkyl-lysophospholipid to target highly aggressive paediatric tumours. These nanoemulsions, with an average diameter of 120 nm and near-neutral zeta potential, remained stable in biological media and penetrated xenografted cancer sites in zebrafish models. In vitro assays demonstrated significant inhibition of tumour cell proliferation, and in vivo studies showed marked reduction in invasive cell growth. This work exemplifies the promise of lipid-based carriers to deliver membrane-active agents selectively to paediatric cancers, laying groundwork for further preclinical assessment and potential clinical translation.

Nanomedicine Applications in Pediatric Cancer Therapy publication trend

The graph below shows the total number of articles in nanomedicine applications in pediatric cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Nanoparticle: A particle with dimensions between 1 and 100 nanometres that can encapsulate or conjugate therapeutic agents for improved delivery.

Nanoemulsion: A thermodynamically metastable dispersion of nanoscale oil droplets in water stabilised by surfactants, used to solubilise lipophilic drugs.

Encapsulation efficiency: The percentage of a drug dose successfully loaded into a nanoparticle relative to the initial amount used.

Zeta potential: The electric potential at the boundary layer of a nanoparticle, influencing stability and interactions with biological systems.

Blood–brain barrier: A selective physiological interface that restricts passage of most molecules from the bloodstream into the central nervous system.

References

1. Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies. Pharmaceutics (2023).
2. Recent Developments in Nanomedicine for Pediatric Cancer. Journal of Clinical Medicine (2021).
3. Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model. Scientific Reports (2021).
4. Biosafety evaluation of etoposide lipid nanomedicines in C. elegans. Drug Delivery and Translational Research (2024).
5. An Update on Emergent Nano-Therapeutic Strategies against Pediatric Brain Tumors. Brain Sciences (2024).